Deskside with Dr. Dan

Take a break and read all about it


FDA grants accelerated approval to Tafasitamab-cxix for diffuse large B-cell lymphoma

As of January 2021, the Food and Drug Administration (FDA) has announced the approval of a new medication for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, who are not eligible for autologous stem cell transplant. The new drug, called Monjuvi (tafasitimab) is a targeted therapy that will be used in combination with lenalidomide (Revlimid). Other combinations are currently under investigation.

Deskside with Dr. Dan

Is a Cancer Clinical Trial Right For You?

Dr. Dan Platt, Gryt Health Chief Medical Officer, explains how to figure out if a cancer clinical trial is the right options for your cancer treatment.

Do You Want To Boost Your Business?

drop us a line and keep in touch